�鶹��

Let’s fast forward to what Wall Street’s brightest and best are watching. Here’s a FREE peek at the latest upgrades from our :

• Healthcare Services Group () gets a Strong Buy upgrade
• 8×8 () is a penny stock with strong potential��
• Why analysts are loving Boston Scientific () right now

P.S. Get more alerts like this daily … Try .

1. Healthcare Services Group ()

This is a sympathy play on the healthcare sector. Healthcare Services Group provides dining, laundry, housekeeping, and general upkeep for healthcare facilities in the U.S. — allowing them to focus on core competencies. With the wider sector rebounding after the difficulties of the pandemic, and HCSG poised to benefit from an aging population, growth prospects are solid at the current asking price, despite a sharp move to the upside in recent days.

Zen Rating: A (Strong Buy) — ����

Recent Price: $14.15 ��— ��

Max 1-year forecast: $17.00��

Why we’re watching:

• At present, HCSG stock has 4 analyst ratings — split evenly between 2 Strong Buys and 2 Holds. ��
• UBS researcher A.J. Rice (a top 11% rated analyst) recently upgraded the stock from a Buy to a Strong Buy, and increased his price target on Healthcare Services Group from $12 to $15.
• The healthcare industry as a whole is bouncing back from the pandemic’s difficult conditions, and the nursing home sector is particularly strong, the analyst said.
• In addition, Rice noted that the company’s “discounted valuation” offers an attractive entry point.
• HCSG is currently the 3rd highest rated stock in the Medical Care Facility industry.
• Healthcare Services Group stock carries a Zen Rating of A, and ranks in the top 2% of stocks overall.
• The stock ranks quite highly in several categories. , in which it ranks in the top 5%, is its strongest Component Grade rating — but Sentiment and Artificial Intelligence, where it ranks in the top 7%, aren’t that far behind.
• In addition, HCSG stock ranks in the 91st percentile according to Growth. ()

2. 8×8 ()��

8×8 provides a unified cloud-based communication and contact center platform geared toward enterprises and mid-sized businesses. Although Wall Street is highly divided in terms of sentiment when it comes to EGHT, it has recently received a vote of confidence from a highly-rated analyst — and it also merits high marks from our rating system.

Zen Rating: A (Strong Buy) — ����

Recent Price: $1.73 — ��

Max 1-year forecast: $3.50��

Why we’re watching:

• Opinions are quite divided regarding 8×8. The stock currently has 6 analyst ratings — 2 Strong Sells, 1 Sell, 1 Hold, 1 Buy, and 1 Strong Buy.
• With that being said, the average 12-month price forecast for EGHT shares currently stands at $2.43, which implies a 33.68% upside.����
• Rosenblatt researcher (a top 7% rated analyst) doubled down on a Strong Buy rating on April 24, while cutting her price target from $3.30 to $2.70.������
• Our proprietary rating system seems to agree with Trebnick rather than dissenting opinions. In fact, EGHT stock carries the highest possible Zen Rating, A, and currently ranks in the 99th percentile of all the equities that we track.
• Moreover, EGHT is currently the 3rd highest rated stock in the entire App industry.
• For a better sense of its specific strengths, we have to take a closer look at 8×8’s Component Grade ratings. The stock ranks in the top 3% according to Value, the top 4% according to Growth, and the top 10% in terms of Safety. ()

3. Boston Scientific ()

Boston Scientific produces a very wide variety of medical devices, from run-of-the-mill pacemakers to advanced stents and brain stimulation systems. BSX is one of the most widely-covered and respected biotech names on Wall Street — and for good reason. Plenty of analysts have revised their coverage following the company’s recent earnings call — and they see plenty of upside to come.

Zen Rating: B (Buy) — ����

Recent Price: $102.17 ��— ��

Max 1-year forecast: $130.00��

Why we’re watching:

• BSX enjoys broad support from Wall Street, with 12 Strong Buy ratings, 4 Buy ratings, and no Hold, Sell, or Strong Sell ratings.
• Truist Securities researcher (a top 5% rated analyst) recently doubled down on a Strong Buy rating, and increased his 12-month price forecast from $113 to $117.
• The analyst’s revised outlook came after Boston Scientific’s Q1 2025 report. Newitter said the “impressive” quarter delivered revenue and margin outperformance, and noted that management’s guidance is absorbing the 2H 2025 tariff impact.
• In fact, Q1 marked the ninth consecutive quarter in which Boston Scientific delivered an earnings per share (EPS) beat.
• BSX shares currently have a Zen Rating of B, and rank in the top 7% of the more than 4,600 equities that we track. Stocks in this class have provided an average annual return of 19.88% since the early 2000s.
• Boston Scientific stock has two key strengths — the first is the fact that it ranks in the top 3% of stocks according to Sentiment. A total of 6 analysts have revised their coverage following the Q1 report — all of them have maintained Buy or Strong Buy ratings, and all of them have increased their price targets.
• BSX also ranks in the top 3% of equities in terms of its Component Grade rating, indicating that a neural network trained on more than 20 years of fundamental and technical data has picked up on subtle signs that hint at future outperformance. ()

What to Do Next?

• ��>